OncoMatch/Clinical Trials/NCT06734572

18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study

Is NCT06734572 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies 18F-FAPIBiotin for malignant neoplasm.

Early Phase 1RecruitingFirst Affiliated Hospital of Fujian Medical UniversityNCT06734572Data as of Jun 2026Location: China

Treatment: 18F-FAPIBiotin — As a new dual targeting PET radiotracer, 18F-FAPI-Biotin is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 18F-FAPI-Biotin in patients with various types of cancer and compared them with the results of 18F-FAPI or 18F-FDG imaging to evaluate the dosimetric characteristics and diagnostic efficacy of 18F-FAPI.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

18F-FAPIBiotin

Cancer type

Tumor Agnostic

Demographics

Ages ≤ 80

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06734572 currently recruiting?

Yes, this trial is currently recruiting patients.

Is there an age limit?

Yes. Patients must be 80 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify